SequelSEC

AVENUE THERAPEUTICS, INC. ATXI

Pharmaceutical Preparations · CIK 0001644963 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$1.40M
Fiscal year ended 2025-12-31
Operating income
-$3.08M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Valuation, from the filing

Public float$571.90KMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.17Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue0.4×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity0.3×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
SBC / revenue47.4%61th
R&D / revenue73.9%39th
Net margin-207.2%47th
Operating margin-219.6%50th

AVENUE THERAPEUTICS, INC. (ATXI) reported revenue of $1.40M and net income of -$2.91M for the fiscal year ended 2025-12-31. This page shows 2 annual periods of income statement, balance sheet and cash flow figures normalized from AVENUE THERAPEUTICS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

AVENUE THERAPEUTICS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Revenue$1.40M$0
Cost of revenueUnavailableUnavailable
Gross profitUnavailableUnavailable
Operating income-$3.08M-$11.28M
Net income-$2.91M-$11.65M
Research & development$1.04M$6.64M
Weighted-average diluted sharesUnavailableUnavailable
Pretax incomeUnavailableUnavailable
Income tax expense$2.00K$0
Diluted EPSUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailable
General & administrative$3.65M$4.64M
Selling & marketingUnavailableUnavailable

Balance

AVENUE THERAPEUTICS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Cash & equivalents$2.86M$2.59M
Total assets$2.93M$2.67M
Current assetsUnavailableUnavailable
Total liabilities$1.10M$816.00K
Current liabilities$1.10M$816.00K
Total equity incl. NCI$1.83M$1.86M
Temporary (mezzanine) equityUnavailableUnavailable
InventoryUnavailableUnavailable
Accounts receivableUnavailableUnavailable
GoodwillUnavailableUnavailable
Long-term debtUnavailableUnavailable
Accounts payableUnavailable$155.00K

Cash flow

AVENUE THERAPEUTICS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Operating cash flow-$1.83M-$9.03M
Capital expendituresUnavailableUnavailable
Investing cash flowUnavailable$0
Financing cash flow$2.09M$9.84M
Net change in cashUnavailableUnavailable
Stock-based compensation$665.00K$1.24M
Common dividends paidUnavailableUnavailable
Common share repurchasesUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailable

Derived

AVENUE THERAPEUTICS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Free cash flowUnavailableUnavailable
Gross marginUnavailableUnavailable
Operating margin-219.6%Unavailable
FCF marginUnavailableUnavailable
SBC / revenue47.4%Unavailable
Current ratioUnavailableUnavailable
Revenue YoY growthUnavailableUnavailable
Net margin-207.2%Unavailable
R&D / revenue73.9%Unavailable
CapEx / revenueUnavailableUnavailable
Long-term debt / equityUnavailableUnavailable
Effective tax rateUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ATXI in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-07View SEC filing
10-Q · Filed 2026-05-08View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.